The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
Breast Neoplasm Female
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
-
Siteman Cancer Center, Saint Louis, Missouri, United States, 63129
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
No
Rna Diagnostics Inc.,
Maureen Trudeau, MD, PRINCIPAL_INVESTIGATOR, Sunnybrook Health Sciences Center, Toronto, Canada
Daniele Generali, MD, PRINCIPAL_INVESTIGATOR, SST di Cremona Multidisciplinare di Patologia Mammaria, Italy
Foluso Ademuyiwa, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine, St Louis, USA
Thierry Petit, MD, PRINCIPAL_INVESTIGATOR, Institut de Cancérologie, Strasbourg, France
Joke Tio, MD, PRINCIPAL_INVESTIGATOR, Munster, Germany
Eva Ciruelos, MD, PRINCIPAL_INVESTIGATOR, Madrid, Spain
Tomasz Jankowski, MD, PRINCIPAL_INVESTIGATOR, NZOZ Neuromed, Lublin, Poland
2030-03-31